84,750 Shares in Boston Scientific Corporation $BSX Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 84,750 shares of the medical equipment provider’s stock, valued at approximately $3,617,000.

Other large investors have also recently added to or reduced their stakes in the company. Kelleher Financial Advisors acquired a new position in Boston Scientific during the 2nd quarter worth $25,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the first quarter worth about $28,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $49.86 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $46.44 and its two-hundred day moving average price is $57.14. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a market capitalization of $72.26 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.07 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has initiated a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Needham & Company LLC cut their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. Truist Financial lowered their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Canaccord Genuity Group dropped their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 194,522 shares of company stock worth $9,385,210 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.